Adc Therapeutics Stock News

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) announced today that its Chief Executive Officer, Ameet Mallik, will be participating in a fireside chat at the Jefferies Healt

Analysts have provided the following ratings for ADC Therapeutics (NYSE:ADCT) within the last quarter: Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 1 3 0 0 0

RBC Capital has decided to maintain its Outperform rating of ADC Therapeutics (NYSE:ADCT) and lower its price target from $34.00 to $30.00. Shares of ADC Therapeutics are trading down 1.34% over the l

ADCT earnings call for the period ending March 31, 2022.

ADC Therapeutics SA (NYSE:ADCT ) Q1 2022 Earnings Conference Call May 9, 2022 8:30 AM ET Company Participants Amanda Hamilton - Investor Relations Manager Chris Martin - Former Chief Executive Officer

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

ADC Therapeutics (ADCT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted an

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted an

Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT) to $26 from $45 and keeps an Overweight rating. Analyst Brian Cheng notes that the r

Following Q4 FY21 results, Cantor Fitzgerald has lowered the price target on ADC Therapeutics SA (NASDAQ: ADCT ) to $26 from $45 and keeps an Overweight rating. Analyst Brian Cheng notes that the repositioning of Zynlonta''s pipeline strategy in diffuse large B-cell lymphoma (DLBCL) came as a surprise, given the multiple Zynlonta combination trials that ADC had ongoing and planned for the near-term. The analyst awaits more color on the Rituxan combination''s differentiation vs. Monjuvi and Polivy near-term. Full story available on Benzinga.com

ADCT earnings call for the period ending December 31, 2021.

ADCT earnings call for the period ending December 31, 2021.